

# CITATION REPORT

List of articles citing

## Profile of Silodosin

**DOI: 10.1016/j.eursup.2010.04.001**  
**European Urology Supplements, 2010, 9, 491-495.**

**Source:** <https://exaly.com/paper-pdf/49623889/citation-report.pdf>

**Version:** 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>International Journal of Urology</i> , <b>2010</b> , 17, 869-75	2.3	27
33	Editorial comment to short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>International Journal of Urology</i> , <b>2010</b> , 17, 875	2.3	0
32	Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia. <i>Drugs</i> , <b>2011</b> , 71, 897-907	2.1	12
31	Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report. <i>Drugs and Aging</i> , <b>2011</b> , 28, 843-5	4.7	4
30	Does the use of silodosin to treat benign prostatic hyperplasia really offer something new?. <i>European Urology</i> , <b>2011</b> , 59, 353-5; discussion 355	10.2	3
29	Reply from Authors re: Giuseppe Morgia. Does the Use of Silodosin to Treat Benign Prostatic Hyperplasia Really Offer Something New? Eur Urol 2011;59:353-5. <i>European Urology</i> , <b>2011</b> , 59, 355	10.2	
28	Silodosin: a guide to its use in benign prostatic hyperplasia. <i>Drugs and Therapy Perspectives</i> , <b>2012</b> , 28, 1-4	1.5	
27	Alpha adrenoreceptor antagonists: have we reached the optimum balance of safety/efficacy?. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2012</b> , 9, e27-e33		
26	Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2085-96	4	23
25	Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. <i>World Journal of Urology</i> , <b>2013</b> , 31, 997-1008	4	22
24	Enantioselective synthesis of (R) Silodosin by ultrasound-assisted diastereomeric crystallization. <i>Tetrahedron</i> , <b>2013</b> , 69, 2834-2843	2.4	8
23	Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. <i>International Journal of Clinical Practice</i> , <b>2013</b> , 67, 544-51	2.9	21
22	A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). <i>BJU International</i> , <b>2014</b> , 114, 427-33	5.6	15
21	Enzymatic asymmetric synthesis of the silodosin amine intermediate. <i>Tetrahedron: Asymmetry</i> , <b>2014</b> , 25, 284-288		14
20	Selecting the right $\alpha$ -blocker: is silodosin your best option?. <i>BJU International</i> , <b>2015</b> , 115, 677-8	5.6	
19	Silodosin is a safer alpha-blocker targeting benign prostatic hyperplasia. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , <b>2015</b> , 57, 291-292	0.6	1
18	Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia. <i>Drugs</i> , <b>2015</b> , 75, 207-17	12.1	13

17	The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with $\alpha$ -blockers: focus on silodosin. <i>Clinical Drug Investigation</i> , <b>2015</b> , 35 Suppl 1, 7-18	3.2	8
16	Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. <i>BJU International</i> , <b>2015</b> , 115, 802-14	5.6	14
15	Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 81, 13-22	3.8	28
14	Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. <i>Biomedicine and Pharmacotherapy</i> , <b>2016</b> , 83, 1141-1145	7.5	9
13	The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis. <i>BMC Urology</i> , <b>2016</b> , 16, 23	2.2	10
12	Benign prostatic hyperplasia. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16031	51.1	132
11	Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , <b>2016</b> , 8, 257-271	3.2	11
10	Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. <i>The Cochrane Library</i> , <b>2017</b> , 11, CD012615	5.2	18
9	Silodosin oral films: Development, physico-mechanical properties and in vitro dissolution studies in simulated saliva. <i>Journal of Drug Delivery Science and Technology</i> , <b>2019</b> , 53, 101122	4.5	7
8	Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology. <i>Advances in Therapy</i> , <b>2019</b> , 36, 1-18	4.1	8
7	Management and treatment. <b>2020</b> , 71-106		
6	Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. <i>Drugs and Aging</i> , <b>2020</b> , 37, 725-738	4.7	24
5	RANDOMIZED TRIAL OF THE SAFETY AND EFFICACY OF TAMSULOSIN AND SILODOSIN IN MEDICAL EXPULSIVE THERAPY FOR DISTAL THIRD URETERIC CALCULI. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2014</b> , 3, 14021-14029	0.1	
4	The Study of Tadalafil and Tamsulosin as Monotherapy for Lower Urinary Tract Symptoms Due to Benign Hyperplasia of Prostate. <i>Journal of Evolution of Medical and Dental Sciences</i> , <b>2019</b> , 8, 3968-3971	0.1	
3	Radiosynthesis, In Vitro and In Vivo Evaluation of $^{99m}\text{Tc}$ -Silodosin as a Tumor Marker in Mice. <i>Radiochemistry</i> , <b>2021</b> , 63, 828-834	0.9	
2	The efficacy and safety of silodosin-a review of literature. <i>Pharmacy &amp; Pharmacology International Journal</i> , <b>2021</b> , 9, 249-256	0.7	
1	Phenols in Pharmaceuticals: Analysis of a Recurring Motif.. <i>Journal of Medicinal Chemistry</i> , <b>2022</b> ,	8.3	7